OneCell Diagnostics is now 1Cell.Ai
OneCell Diagnostics is now 1Cell.Ai
OncoMonitor® enables oncologists to track disease activity and residual disease in real time — allowing early interventions before clinical relapse becomes visible.
OncoMonitor® TRM: Treatment Response Monitoring and Resistance Tracking
OncoMonitor® MRD: Minimal Residual Disease Detection after therapy
Longitudinal tracking of disease dynamics using blood-based biomarkers
Real-time assessment of treatment efficacy and emerging resistance
Early detection of minimal residual disease (MRD)
Supports prognosis prediction based on CTC and ctDNA trends
AI-powered reporting for rapid, comprehensive insights
Measures circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) levels from plasma samples.
Regular blood draws allow dynamic assessment of disease burden, therapy response, and relapse risk over time.
Trace amounts of ctDNA and CTCs post-treatment signal the presence of residual disease before clinical or radiological signs.
Swift, accurate, and dynamic reports generated through the iCARE™ AI-powered analysis platform.
Monitor cancer patients throughout their treatment journey
Adjust therapies based on molecular response or resistance markers
Detect relapse earlier than conventional imaging
Minimize invasive procedures with blood-based monitoring
Gain earlier, actionable insights for personalized care adjustments
Covers both early stage and advanced metastatic disease monitoring
Enables treatment efficacy assessment through longitudinal CTC/ctDNA tracking
Identifies resistance mechanisms and molecular relapse signals
AI-driven, real-time reporting enhances decision-making speed and accuracy
| Cancer Type | Key Genes |
|---|---|
| Lung | EGFR, KRAS, MET, ALK, ROS1, RET, TP53, PIK3CA, HRAS, FGFR1/2/3, ERBB2, NRAS, NTRK1/2/3, MAP2K1, PTEN |
| Breast | BRCA1, BRCA2, HER2 (ERBB2), PIK3CA, ESR1, PALB2, TP53, FGFR1/2/3 |
| Colorectal | KRAS, NRAS, BRAF, TP53, SMAD4, MLH1, MSH2, MSH6, PMS2, PIK3CA, MET |
| Melanoma | BRAF, NRAS, KIT, PDGFRA, CTNNB1, HRAS, PIK3CA |
| Gastrointestinal | KRAS, BRAF, PDGFRA, KIT, MET, SMAD4, MLH1, MSH2, NTRK1/2/3, TP53 |
| Ovary | BRCA1, BRCA2, PALB2, BRAF, KRAS, NRAS, TP53 |
| Bladder | TP53, TSC1, MLH1, MSH2, MSH6, PMS2, NTRK1/2/3 |
| Sensitivity | 90.5% |
| Specificity | 97.2% |
| Positive Predictive Value (PPV) | 95% |
| Negative Predictive Value (NPV) | 94.6% |
| Concordance | 94.7% |
| Limit of Detection (LOD) | 0.05 |
| Longitudinal Monitoring | Assess disease burden dynamically over time |
| Minimal Residual Disease Detection | Identify occult disease post-therapy |
| Real-Time Results | Swift, AI-powered reporting to support clinical decisions |
| Prognostic Value | Predict outcomes based on molecular response trends |
